Atypical Antipsychotics for Adjunctive Treatment of MDD: Advancing the Standard of Care

Thursday, September 7, 2023

10:30 AM – 11:45 AM CT

Location: Davidson B

Speaker(s)

Greg Mattingly, MD

Associate Clinical Professor, Washington University in St. Louis; President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders
St.Charles Psychiatric Associates
Washington University School of Medicine
Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla, NY
New York Medical College

Major depressive disorder (MDD) is plagued by inadequate treatment response and associated with significant negative quality of life (QoL) and high costs; it is estimated that less than half of patients with MDD respond to antidepressant therapy and only half of patients will ever achieve remission. This MasterClass session will explore the burden and unmet needs associated with MDD, with a special focus on patients who exhibit inadequate or partial responses to antidepressant monotherapy. In this session you will learn to identify and evaluate patient characteristics that signal a need for adjunctive treatment, enabling them to make informed decisions for tailored care. Through an in-depth exploration of the mechanisms of approved atypical antipsychotics in the context of adjunctive MDD treatment, you will gain a comprehensive understanding of how these agents impact multiple receptor systems. Furthermore, expert faculty will critically evaluate the efficacy and safety of atypical antipsychotics approved for adjunctive MDD treatment, ensuring that participants are equipped with the latest evidence-based insights. By integrating patient-centered care strategies and utilizing available clinical guidance, attendees will be prepared to confidently tailor appropriate adjunctive treatments for patients facing inadequate or partial responses to antidepressant therapy. Don't miss this unique opportunity to enhance your knowledge in MDD management and elevate the quality of care for your patients.

This session is supported by an educational grant from AbbVie Inc.

Learning Objectives:

Describe the burden and unmet needs associated with MDD, particularly with regard to inadequate/partial response to antidepressant monotherapy
Identify and evaluate the characteristics of patients with inadequate/partial response to antidepressant monotherapy who may benefit from adjunctive treatment
Assess the mechanisms of approved atypical antipsychotics in the context of adjunctive treatment for MDD (eg, the effects of a combined treatment on multiple receptor systems)
Evaluate the efficacy and safety of atypical antipsychotics approved for the adjunctive treatment of MDD
Employ patient-centered care strategies and available clinical guidance to tailor appropriate adjunctive treatment for patients with inadequate/partial response to antidepressant therapy